Moderna Stock News

Victorian Acting Premier James Merlino says Melbourne is one of three leading cities in medical research and biotechnology, with a deal announced which will see the state produce millions of mRNA vaccine doses a year. The federal government has secured a deal with Moderna, with a plant to be built which will produce 25 million doses, including booster shots, each year from 2024. "This is a huge announcement," Mr Merlino said during a media conference on Tuesday. "This is the place to be - Boston, London and Melbourne, the three great leading cities when it comes to medical research and biotechnology." He said across Melbourne and Victoria there are at least 30,000 jobs in medical research and biotechnology across the industry, university and institutes, and 40 per cent of the nation''s medical technology and biotechnology companies are based in Melbourne. "So this is a great announcement and it''s the logical place to do it."

Australia will be able to produce 100 million mRNA vaccines each year as part of a major deal for a new vaccine facility to be built locally with Moderna.

Late on Friday, December 10th, Swiss medicines agency Swissmedic approved Covid vaccinations for children aged between 5 and 11. Previously, vaccination was only available for children aged 12 and up. Which vaccine will be administered? The Pfizer/Biontech vaccine has been approved for children in that age group. Only the Pfizer/Biontech, Moderna and the Johnson and []

Vancouver, British Columbia TheNewswire - December 13, 2021 Blackhawk Growth Corp. (CSE:BLR ) ; (CNSX:BLR.CN); (OTC:BLRZF); ( Frankfurt:0JJ) ( Blackhawk ), is pleased to provide an update on its clinical trials for both of its wholly-owned subsidiaries MindBio Therapeutics PTY Ltd. ( MindBio ) and Digital Mind Technology PTY Ltd. ( Digital Mind ). MindBio Clinical Trial Update MindBio is accelerating its clinical trial program and is now fully funded for its Phase II clinical trial for microdosing of psychedelics in late-stage cancer patients. MindBio will be one of only a handful companies that is progressing to a Phase II clinical trial in the psychedelics sector. The now fully funded Phase II clinical trial will examine the effects of Psychedelic Microdosing Assisted Meaning Centred Psychotherapy (PMA-MCP) in advanced stage cancer patients. The ground-breaking Phase II trial will examine the feasibility, acceptability and safety of a randomised, double-blind, placebo-controlled trial comparing Psychedelic Microdosing Assisted Meaning Centred Psychotherapy (PMA-MCP) to placebo in advanced stage cancer patients.

This article was originally published on TipRanks.com Moderna, Inc. The post Moderna Accelerates COVID-19 Vaccine Supply to COVAX appeared first on Smarter Analyst .

The Qraft AI-Enhanced US Large Cap Momentum ETF (NYSE: AMOM ), an exchange-traded fund driven by artificial intelligence, has acquired new stakes in Tesla Inc. (NASDAQ: TSLA ), Netflix Inc. (NASDAQ: NFLX ) and Autodesk Inc. (NASDAQ: ADSK ), while entirely divesting its holdings in Intel Corp. (NASDAQ: INTC ), PayPal Holdings Inc . (NASDAQ: PYPL ) and Moderna Inc. (NASDAQ: MRNA ). What Happened : The ETFs latest portfolio after rebalancing in early December showed that it has also entirely divested its holdings in technology company International Business Machines Corp. (NYSE: IBM ) and oil giant ConocoPhillips (NYSE: COP ). The ETF, which has assets under management of $27.07 million, has a history of accurately predicting the price movements of Teslas shares. The fund now has electric vehicle maker Full story available on Benzinga.com

Moderna, Inc. (NASDAQ:MRNA) with the stream of -5.57% also noticed, India Energy Transfer LP (NYSE:ET) encountered a rapid change of -1.05% in the last hour of Fridays trading session. Moderna, The post Technical Snapshots for Investors: Moderna, Inc. (NASDAQ:MRNA), Energy Transfer LP (NYSE:ET) appeared first on Stocks Equity .

''For official requirements, it''s still two shots of the mRNA (Pfizer or Moderna) and one shot of the J&J for the official determination of what''s required or not,'' Fauci told ABC News on Sunday.

Railway Pension Investments Ltd acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 15,900 shares of the companys stock, valued at approximately $6,119,000. Other institutional investors and hedge funds also recently bought []

BOOSTER jabs are being made available for every eligible Brit over the age of 18 in the hope they will curb the rapid rise of Omicron infections in the UK. How effective are booster jabs against Omicron? Read more here Daily Express :: Health Feed Is the booster effective against Omicron? Pfizer, AstraZeneca, Moderna latest insight

Australians will now be able to receive a Moderna or a Pfizer booster shot five months after their last vaccination after new evidence showing immunity to the Omicron variant waning six months after a second dose.

Australia is cutting the standard waiting time for a booster shot to five months from six, following the first two doses

Pfizer Jab Is Only 23% Effective Against Omicron, South African Study Finds A few days ago, researchers in South Africa shared data from a preliminary study showing that the Pfizer vaccine is less effective at blocking the omicron variant than earlier variants like beta and delta. Now, the team is telling us exactly how much less effective the vaccine is. According to the same data gleaned from the blood plasma taken from 12 patients who tested positive for omicron, the team found that a two-shot course of Pfizer''s vaccine has just 22.5% efficacy against symptomatic infection with the omicron variant, though it can thwart severe disease, according to laboratory experiments in South Africa, according to Bloomberg. The data comes courtesy of a team of researchers at the Africa Health Research Institute in Durban. Though data has been pouring out about omicron, and sometimes individual studies reach opposing findings, the general consensus is that omicron will be able to more easily evade protection afforded from the first generation of vaccines - however, the scientists say that people will still be protected against severe disease and death.